Anti-MAVS antibody [EPR26357-91],Abcam,AB290729
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
ICC/IF, Flow Cyt (Intra), IP, WB, IHC-P
Platform ID
BAB254599556
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Adapter required for innate immune defense against viruses (PubMed : 16125763, PubMed : 16127453, PubMed : 16153868, PubMed : 16177806, PubMed : 19631370, PubMed : 20127681, PubMed : 20451243, PubMed : 21170385, PubMed : 23087404, PubMed : 27992402, PubMed : 33139700, PubMed : 37582970). Acts downstream of DHX33, RIGI and IFIH1/MDA5, which detect intracellular dsRNA produced during viral replication, to coordinate pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to the subsequent induction of antiviral cytokines such as IFNB and RANTES (CCL5) (PubMed : 16125763, PubMed : 16127453, PubMed : 16153868, PubMed : 16177806, PubMed : 19631370, PubMed : 20127681, PubMed : 20451243, PubMed : 20628368, PubMed : 21170385, PubMed : 23087404, PubMed : 25636800, PubMed : 27736772, PubMed : 33110251). Peroxisomal and mitochondrial MAVS act sequentially to create an antiviral cellular state (PubMed : 20451243). Upon viral infection, peroxisomal MAVS induces the rapid interferon-independent expression of defense factors that provide short-term protection, whereas mitochondrial MAVS activates an interferon-dependent signaling pathway with delayed kinetics, which amplifies and stabilizes the antiviral response (PubMed : 20451243). May activate the same pathways following detection of extracellular dsRNA by TLR3 (PubMed : 16153868). May protect cells from apoptosis (PubMed : 16125763). Involved in NLRP3 inflammasome activation by mediating NLRP3 recruitment to mitochondria (PubMed : 23582325). See full target information MAVS
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.